Atlas Trials

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Clinical trial NCT04317534 · RECRUITING

Trial details

NCT number
NCT04317534
Sponsor
Greg Durm, MD
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
NSCLC, Stage I
Start date
2020-05-05
Primary completion
2027-04-08
Enrollment
244

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.